Literature DB >> 21562798

Polycystic ovary syndrome: a common endocrine disorder and risk factor for vascular disease.

Mary P McGowan1.   

Abstract

OPINION STATEMENT: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy among women of reproductive age, impacting 5-10% of premenopausal American women. During the reproductive years, women with PCOS seek medical attention related to infertility, hirsutism, and acne. About 60% of women with PCOS are obese and insulin resistant. Up to 40% of women with PCOS will develop diabetes by the age of 50 and many are dyslipidemic. In addition to treating the cosmetic and fertility issues associated with PCOS, health care providers must educate patients regarding the long-term cardiovascular consequences associated the this disorder. At menopause, a woman with PCOS is likely to have had multiple cardiac risk factors for several decades. Postmenopausal women with a history of PCOS, especially those with established diabetes and/or dyslipidemia, should be considered at high risk for the development of clinical cardiac disease. Exercise and a prudent calorie-restricted diet aimed at weight loss must be stressed early. Pharmacologic therapy for diabetes and hyperlipidemia should be used when appropriate. Bariatric surgery, known to positively impact all the aforementioned cardiac risk factors, may also be of benefit.

Entities:  

Year:  2011        PMID: 21562798     DOI: 10.1007/s11936-011-0130-0

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  37 in total

1.  Obesity and insulin resistance but not hyperandrogenism mediates vascular dysfunction in women with polycystic ovary syndrome.

Authors:  Anuja Dokras; Dinesh H Jagasia; Michelle Maifeld; Christine A Sinkey; Bradley J VanVoorhis; William G Haynes
Journal:  Fertil Steril       Date:  2006-10-24       Impact factor: 7.329

2.  Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study.

Authors:  Thomas Tang; Julie Glanville; Catherine J Hayden; Davinia White; Julian H Barth; Adam H Balen
Journal:  Hum Reprod       Date:  2005-09-30       Impact factor: 6.918

Review 3.  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.

Authors:  A Dunaif
Journal:  Endocr Rev       Date:  1997-12       Impact factor: 19.871

Review 4.  Pitavastatin.

Authors:  R Y A Mukhtar; J Reid; J P D Reckless
Journal:  Int J Clin Pract       Date:  2005-02       Impact factor: 2.503

5.  Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial.

Authors:  Xavier Pi-Sunyer; George Blackburn; Frederick L Brancati; George A Bray; Renee Bright; Jeanne M Clark; Jeffrey M Curtis; Mark A Espeland; John P Foreyt; Kathryn Graves; Steven M Haffner; Barbara Harrison; James O Hill; Edward S Horton; John Jakicic; Robert W Jeffery; Karen C Johnson; Steven Kahn; David E Kelley; Abbas E Kitabchi; William C Knowler; Cora E Lewis; Barbara J Maschak-Carey; Brenda Montgomery; David M Nathan; Jennifer Patricio; Anne Peters; J Bruce Redmon; Rebecca S Reeves; Donna H Ryan; Monika Safford; Brent Van Dorsten; Thomas A Wadden; Lynne Wagenknecht; Jacqueline Wesche-Thobaben; Rena R Wing; Susan Z Yanovski
Journal:  Diabetes Care       Date:  2007-03-15       Impact factor: 19.112

Review 6.  Mechanism of action of niacin.

Authors:  Vaijinath S Kamanna; Moti L Kashyap
Journal:  Am J Cardiol       Date:  2008-04-17       Impact factor: 2.778

Review 7.  The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome.

Authors:  E Diamanti-Kandarakis; E Kandaraki; C Christakou; D Panidis
Journal:  Obes Rev       Date:  2009-04-21       Impact factor: 9.213

8.  Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial.

Authors:  Asa Lindholm; Marie Bixo; Inger Björn; Pål Wölner-Hanssen; Mats Eliasson; Anders Larsson; Owe Johnson; Inger Sundström Poromaa
Journal:  Fertil Steril       Date:  2007-07-02       Impact factor: 7.329

9.  Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial.

Authors:  Christopher D Gardner; Alexandre Kiazand; Sofiya Alhassan; Soowon Kim; Randall S Stafford; Raymond R Balise; Helena C Kraemer; Abby C King
Journal:  JAMA       Date:  2007-03-07       Impact factor: 56.272

10.  Is there an independent effect of polycystic ovary syndrome (PCOS) and menopause on the prevalence of subclinical atherosclerosis in middle aged women?

Authors:  Evelyn O Talbott; Jeanne Zborowski; Judy Rager; Juley R Stragand
Journal:  Vasc Health Risk Manag       Date:  2008
View more
  9 in total

1.  Defining the role of bariatric surgery in polycystic ovarian syndrome patients.

Authors:  Shaveta M Malik; Michael L Traub
Journal:  World J Diabetes       Date:  2012-04-15

2.  Polycystic Ovarian Syndrome: An Autobiographical Case Report of an Often Overlooked Disorder.

Authors:  Vithi Hitendra Patel
Journal:  Cureus       Date:  2022-01-12

3.  Evaluation of the Prevalence, Regional Phenotypic Variation, Comorbidities, Risk Factors, and Variations in Response to Different Therapeutic Modalities Among Indian Women: Proposal for the Indian Council of Medical Research-Polycystic Ovary Syndrome (ICMR-PCOS) Study.

Authors:  Mohd Ashraf Ganie; Subhankar Chowdhury; Vanita Suri; Beena Joshi; Prasanta Kumar Bhattacharya; Sarita Agrawal; Neena Malhotra; Rakesh Sahay; Roya Rozati; Puthiyaveettil Khadar Jabbar; Vishnubhatla Sreenivas; Mukesh Sriwastva; Imtiyaz Ahmad Wani; Shalini Singh; Radhey Shyam Sharma
Journal:  JMIR Res Protoc       Date:  2021-08-27

4.  Cardiometabolic Effects of Chronic Hyperandrogenemia in a New Model of Postmenopausal Polycystic Ovary Syndrome.

Authors:  Carolina Dalmasso; Rodrigo Maranon; Chetan Patil; Elizabeth Bui; Mohadetheh Moulana; Howei Zhang; Andrew Smith; Licy L Yanes Cardozo; Jane F Reckelhoff
Journal:  Endocrinology       Date:  2016-05-04       Impact factor: 4.736

5.  Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy.

Authors:  Maria Vinaixa; Miguel Angel Rodriguez; Sara Samino; Marta Díaz; Antoni Beltran; Roger Mallol; Cinta Bladé; Lourdes Ibañez; Xavier Correig; Oscar Yanes
Journal:  PLoS One       Date:  2011-12-16       Impact factor: 3.240

6.  A study of ghrelin and leptin levels and their relationship to metabolic profiles in obese and lean Saudi women with polycystic ovary syndrome (PCOS).

Authors:  Maha H Daghestani; Mazin Daghestani; Mamoon Daghistani; Akmal El-Mazny; Geir Bjørklund; Salvatore Chirumbolo; Samar H Al Saggaf; Arjumand Warsy
Journal:  Lipids Health Dis       Date:  2018-08-21       Impact factor: 3.876

7.  Awareness of polycystic ovary syndrome among obstetrician-gynecologists and endocrinologists in Northern Europe.

Authors:  Terhi T Piltonen; Maria Ruokojärvi; Helle Karro; Linda Kujanpää; Laure Morin-Papunen; Juha S Tapanainen; Elisabet Stener-Victorin; Inger Sundrström-Poromaa; Angelica L Hirschberg; Pernille Ravn; Dorte Glintborg; Jan Roar Mellembakken; Thora Steingrimsdottir; Melanie Gibson-Helm; Eszter Vanky; Marianne Andersen; Riikka K Arffman; Helena Teede; Kobra Falah-Hassani
Journal:  PLoS One       Date:  2019-12-26       Impact factor: 3.240

Review 8.  Spironolactone Versus Oral Contraceptive Pills in the Treatment of Adolescent Polycystic Ovarian Syndrome: A Systematic Review.

Authors:  Shriya Rajashekar; Suganya Giri Ravindran; Meghana Kakarla; Musa Ausaja Gambo; Mustafa Yousri Salama; Nathalie Haidar Ismail; Pardis Tavalla; Pulkita Uppal; Shaza A Mohammed; Pousette Hamid
Journal:  Cureus       Date:  2022-05-25

Review 9.  Metabolic disorders in menopause.

Authors:  Grzegorz Stachowiak; Tomasz Pertyński; Magdalena Pertyńska-Marczewska
Journal:  Prz Menopauzalny       Date:  2015-03-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.